# Rafael Rosell

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/rafael-rosell/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,223 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 94 |
| i10-index | 428 |
| Last Known Institution | Instituto Oncológico Dr. Rosell |
| OpenAlex ID | https://openalex.org/A5044887899 |
| ORCID iD | https://orcid.org/0000-0003-0817-3400 |
| Works | 1,002 |

## Researcher papers

Showing 12 of 16.

- [Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group](https://scholariq.org/papers/lung-adjuvant-cisplatin-evaluation-a-pooled-analysis-by-the-lace-collaborative/)
- [Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-versus-crizotinib-in-untreated-i-alk-i-positive-non-small-cell-lung/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer](https://scholariq.org/papers/activation-of-the-axl-kinase-causes-resistance-to-egfr-targeted-therapy-in-lung/)
- [Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/dacomitinib-versus-gefitinib-as-first-line-treatment-for-patients-with-egfr/)
- [Non-small-cell lung cancer](https://scholariq.org/papers/non-small-cell-lung-cancer/)
- [Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients.](https://scholariq.org/papers/detection-of-aberrant-promoter-hypermethylation-of-tumor-suppressor-genes-in/)
- [Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study](https://scholariq.org/papers/updated-overall-survival-and-final-progression-free-survival-data-for-patients/)
- [Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations](https://scholariq.org/papers/improvement-in-overall-survival-in-a-randomized-study-that-compared-dacomitinib/)
- [Adjuvant chemotherapy for resected early-stage non-small cell lung cancer](https://scholariq.org/papers/adjuvant-chemotherapy-for-resected-early-stage-non-small-cell-lung-cancer/)
- [Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer](https://scholariq.org/papers/prognostic-effect-of-tumor-lymphocytic-infiltration-in-resectable-non-small-cell/)
- [Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial](https://scholariq.org/papers/activity-and-safety-of-brigatinib-in-alk-rearranged-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Instituto Oncológico Dr. Rosell](https://scholariq.org/institutions/instituto-oncologico-dr-rosell/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.